Compare Stocks: SLS, HALO, ARWR, and MDGL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$84.91 -4.2%	$83.64	$21.61 ▼ $95.49	$11.96B	1.27	1.13 million shs	1.28 million shs
HALO Halozyme Therapeutics	$105.35 -1.5%	$87.01	$61.22 ▼ $109.66	$11.96B	0.85	2.37 million shs	1.68 million shs
MDGL Madrigal Pharmaceuticals	$533.76 -1.8%	$526.96	$393.61 ▼ $615.00	$12.33B	-1.01	321,180 shs	268,664 shs
SLS SELLAS Life Sciences Group	$13.21 -13.1%	$12.48	$1.39 ▼ $15.88	$2.67B	2.48	6.80 million shs	9.77 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	-2.53%	-2.76%	+8.98%	+289.67%
HALO Halozyme Therapeutics	0.00%	-2.61%	+26.47%	+58.33%	+43.96%
MDGL Madrigal Pharmaceuticals	0.00%	+3.29%	+8.24%	+7.34%	+25.57%
SLS SELLAS Life Sciences Group	0.00%	-14.55%	+28.38%	+41.89%	+588.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$84.91 -4.2%	$83.64	$21.61 ▼ $95.49	$11.96B	1.27	1.13 million shs	1.28 million shs
HALO Halozyme Therapeutics	$105.35 -1.5%	$87.01	$61.22 ▼ $109.66	$11.96B	0.85	2.37 million shs	1.68 million shs
MDGL Madrigal Pharmaceuticals	$533.76 -1.8%	$526.96	$393.61 ▼ $615.00	$12.33B	-1.01	321,180 shs	268,664 shs
SLS SELLAS Life Sciences Group	$13.21 -13.1%	$12.48	$1.39 ▼ $15.88	$2.67B	2.48	6.80 million shs	9.77 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	-2.53%	-2.76%	+8.98%	+289.67%
HALO Halozyme Therapeutics	0.00%	-2.61%	+26.47%	+58.33%	+43.96%
MDGL Madrigal Pharmaceuticals	0.00%	+3.29%	+8.24%	+7.34%	+25.57%
SLS SELLAS Life Sciences Group	0.00%	-14.55%	+28.38%	+41.89%	+588.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.62	Moderate Buy	$97.33	14.63% Upside
HALO Halozyme Therapeutics	2.62	Moderate Buy	$91.20	-13.43% Downside
MDGL Madrigal Pharmaceuticals	2.78	Moderate Buy	$699.64	31.08% Upside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	-24.30% Downside

Current Analyst Ratings Breakdown

Latest SLS, HALO, ARWR, and MDGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	ARWR Arrowhead Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/14/2026	HALO Halozyme Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/12/2026	SLS SELLAS Life Sciences Group	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	HALO Halozyme Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/7/2026	HALO Halozyme Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$96.00 ➝ $105.00
8/7/2026	HALO Halozyme Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$92.00 ➝ $93.00
8/7/2026	HALO Halozyme Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$75.00 ➝ $95.00
8/7/2026	HALO Halozyme Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$83.00 ➝ $110.00
8/7/2026	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$95.00 ➝ $115.00
8/6/2026	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$115.00 ➝ $120.00
8/4/2026	MDGL Madrigal Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$605.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$829.45M	14.42	$0.12 per share	711.14	$3.31 per share	25.65
HALO Halozyme Therapeutics	$1.40B	8.56	$4.77 per share	22.08	$1.26 per share	83.61
MDGL Madrigal Pharmaceuticals	$1.28B	9.60	N/A	N/A	$22.67 per share	23.54
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.68 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.25	N/A	N/A	N/A	-47.79%	-60.06%	-17.37%	N/A
HALO Halozyme Therapeutics	$316.89M	$3.35	31.45	11.38	0.42	24.86%	260.98%	23.91%	11/2/2026 (Estimated)
MDGL Madrigal Pharmaceuticals	-$288.28M	-$12.89	N/A	96.17	N/A	-25.32%	-56.65%	-25.53%	11/3/2026 (Estimated)
SLS SELLAS Life Sciences Group	-$26.86M	-$0.21	N/A	N/A	N/A	N/A	-35.91%	-33.34%	11/11/2026 (Estimated)

Latest SLS, HALO, ARWR, and MDGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	-$0.05	-$0.0050	-$0.05	N/A	N/A
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million
7/30/2026	Q2 2026	MDGL Madrigal Pharmaceuticals	-$2.68	-$1.99	+$0.69	-$1.99	$352.13 million	$364.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.77	5.90	5.90
HALO Halozyme Therapeutics	13.50	2.71	2.31
MDGL Madrigal Pharmaceuticals	0.65	3.20	2.94
SLS SELLAS Life Sciences Group	N/A	18.83	18.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
HALO Halozyme Therapeutics	97.79%
MDGL Madrigal Pharmaceuticals	98.50%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
HALO Halozyme Therapeutics	2.50%
MDGL Madrigal Pharmaceuticals	17.60%
SLS SELLAS Life Sciences Group	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	140.86 million	135.79 million	Optionable
HALO Halozyme Therapeutics	390	113.50 million	110.66 million	Optionable
MDGL Madrigal Pharmaceuticals	90	23.10 million	19.04 million	Optionable
SLS SELLAS Life Sciences Group	10	201.95 million	199.32 million	Not Optionable

SLS, HALO, ARWR, and MDGL Headlines

Recent News About These Companies

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down - Here's What Happened

August 28 at 11:59 AM | marketbeat.com

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 8.8% - Still a Buy?

August 27 at 11:59 AM | marketbeat.com

Sellas Traders See Pancreatic Cancer Race After RVMD’s Drug Approval — But Near-Term Focus Remains On SLS’s Leukemia Pipeline

August 26, 2026 | msn.com

Sellas Life Sciences: A LinkedIn Post Moves the Stock While the Official Filing Stays Silent

August 26, 2026 | ad-hoc-news.deA

SLS traders eye this important resistance zone ahead of key AML data readout

August 24, 2026 | msn.com

SELLAS Life Sciences (SLS) Stock Rockets 255% on Phase 3 Leukemia Trial Progress

August 24, 2026 | blockonomi.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 8.4% - Time to Sell?

August 24, 2026 | marketbeat.com

Quantinno Capital Management LP Takes $315,000 Position in SELLAS Life Sciences Group, Inc. $SLS

August 24, 2026 | marketbeat.com

Investors Buy Large Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)

August 23, 2026 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Decibel Cannabis Company (OtherDBCCF) and SELLAS Life Sciences Group (SLS)

August 22, 2026 | theglobeandmail.com

SLS stock clocks three straight weeks of gains on cancer vaccine spillover, REGAL trial data anticipation

August 22, 2026 | msn.com

Traders Purchase Large Volume of SELLAS Life Sciences Group Call Options (NASDAQ:SLS)

August 21, 2026 | marketbeat.com

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 10% Higher - Still a Buy?

August 21, 2026 | marketbeat.com

SELLAS Life Sciences Group (SLS) Stock Looks Stretched Despite Key AML Trial Progress

August 21, 2026 | finance.yahoo.com

Sellas CEO Angelos Stergiou Highlights Pediatric Leukemia Study That ‘Directly Supports’ Scientific Basis Of Regal Trial

August 17, 2026 | finance.yahoo.com

This One Data Readout Could Make Or Break Sellas Life Sciences Group

August 13, 2026 | seekingalpha.com

Sellas’ experimental drug SLS009 appears to be leading the CDK9 race, says Alliance Global – analyst sees about 200% upside potential

August 12, 2026 | msn.com

Investors Buy High Volume of SELLAS Life Sciences Group Put Options (NASDAQ:SLS)

August 12, 2026 | marketbeat.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - Time to Buy?

August 12, 2026 | marketbeat.com

SELLAS Life Sciences Group, Inc. $SLS is Dagco Inc.'s 10th Largest Position

August 12, 2026 | marketbeat.com

Sellas Life Sciences reports wider loss as REGAL trial nears final analysis

August 11, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SLS, HALO, ARWR, and MDGL Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$84.91 -3.68 (-4.15%)

As of 08/28/2026 04:00 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Halozyme Therapeutics NASDAQ:HALO

$105.35 -1.57 (-1.47%)

As of 08/28/2026 04:00 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$533.76 -9.93 (-1.83%)

As of 08/28/2026 04:00 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

SELLAS Life Sciences Group NASDAQ:SLS

$13.21 -2.00 (-13.15%)

As of 08/28/2026 04:00 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLS, HALO, ARWR, and MDGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLS, HALO, ARWR, and MDGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLS, HALO, ARWR, and MDGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SLS, HALO, ARWR, and MDGL Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Halozyme Therapeutics NASDAQ:HALO

Madrigal Pharmaceuticals NASDAQ:MDGL

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLS, HALO, ARWR, and MDGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLS, HALO, ARWR, and MDGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLS, HALO, ARWR, and MDGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SLS, HALO, ARWR, and MDGL Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Halozyme Therapeutics NASDAQ:HALO

Madrigal Pharmaceuticals NASDAQ:MDGL

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools